The major players in the NGS-based RNA-seq market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N. V. (Germany), Pacific Biosciences of California, Inc. (U.S.), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg).
The factors driving the growth of this market are the advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-seq grants, increasing number of research activities, and rapid growth in precision medicine. However, accuracy and standardization concerns in diagnostic testing and the lack of skilled professionals are some of the key factors hindering the growth of the market.
Analysis of the market developments between 2014 and 2017 (January) reveals that product launches, product enhancements, and service launches were the most widely adopted growth strategies by players in the market. Players adopted these strategies to strengthen their product portfolios and maintain a competitive position in the market.
Market players also adopted strategic partnerships and collaborations to strengthen their market position by developing and providing technologically advanced products to its customer base. For instance, in October 2016, Lexogen GmbH (Austria) collaborated with Bluebee Holding B.V. (Netherlands) with the aim to simplify gene expression RNA-seq data analysis. Similarly, in August 2016, Illumina, Inc. (U.S.) entered into a partnership with FlowJo, LLC (U.S.), a data analysis software provider, for developing and co-marketing its single-cell next-generation sequencing (NGS) data analysis software. As per the agreement, a new software application capable of integrating smoothly with Illumina’s Single Cell RNA BaseSpace app will be developed by FlowJo, LLC.
Thermo Fisher Scientific is a leading market player with its extensive range of NGS-based RNA-seq products, including analytical instruments, equipment, reagents and consumables, software & services for research, analysis, discovery, and diagnostics. In addition to a robust product portfolio, the company has a substantial geographic presence.
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly